Aytu Biopharma (AYTU) Enterprise Value (2016 - 2025)
Aytu Biopharma (AYTU) has disclosed Enterprise Value for 14 consecutive years, with -$30.0 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value fell 47.2% to -$30.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$30.0 million, a 47.2% decrease, with the full-year FY2025 number at -$31.0 million, down 54.71% from a year prior.
- Enterprise Value was -$30.0 million for Q4 2025 at Aytu Biopharma, up from -$32.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$18.2 million in Q1 2025 to a low of -$50.2 million in Q2 2021.
- A 5-year average of -$28.0 million and a median of -$25.7 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 61.4% in 2022, then plummeted 62.27% in 2025.
- Aytu Biopharma's Enterprise Value stood at -$35.3 million in 2021, then skyrocketed by 32.5% to -$23.8 million in 2022, then grew by 3.47% to -$23.0 million in 2023, then increased by 11.26% to -$20.4 million in 2024, then crashed by 47.2% to -$30.0 million in 2025.
- Per Business Quant, the three most recent readings for AYTU's Enterprise Value are -$30.0 million (Q4 2025), -$32.6 million (Q3 2025), and -$31.0 million (Q2 2025).